David Joffe, BSPharm, CDE
The cardiovascular morbidity and mortality associated with diabetes are well established, so much so that type 2 diabetes has been described as a cardiovascular disease presenting as a metabolic disorder. Patients with type 2 diabetes are particularly at risk for atherosclerosis; so medications with ancillary vascular benefits are particularly useful, and the effects of glucose-lowering medications are of interest with regards to their effects on markers of cardiovascular health. Glucagon-like peptide-1 (GLP-1) receptors are widely expressed in a number of tissues including the myocardium and cardiovasculature, and GLP-1 appears to have a range of neurotrophic, neuroprotective and cardioprotective effects. As a consequence, there seems to be potential therapeutic benefit from these drugs….
… Read the Rest
- Keywords: diabetes, diabetes newsletter, diabetic newsletter, diabetes, news for diabetics, news for doctors, diabetes in children, diabetes in control, health, blood sugars, diabetes type 1, diabetes type 2, health care, blood sugars, low blood sugars, lower blood sugars, a1cnow, hba1c, hemoglobin a1c, sportbrain, tacticon, diabetes care, pharmacy
- Description: Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better help their diabetes patients.